A citation-based method for searching scientific literature

Soledad Jorge, Andrew S McFaddin, Kemi M Doll, Kathryn P Pennington, Barbara M Norquist, Robin L Bennett, Colin C Pritchard, Elizabeth M Swisher. Gynecol Oncol 2020
Times Cited: 6







List of co-cited articles
23 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
717
83

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
335
66

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N Grisham, Paul J Goodfellow, Elise C Kohn, Douglas A Levine, Joyce F Liu, Karen H Lu,[...]. J Clin Oncol 2020
44
50

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
Ettore Capoluongo, Gillian Ellison, José Antonio López-Guerrero, Frederique Penault-Llorca, Marjolijn J L Ligtenberg, Susana Banerjee, Christian Singer, Eitan Friedman, Birgid Markiefka, Peter Schirmacher,[...]. Semin Oncol 2017
49
50

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2016
232
50

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
575
33

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
968
33

ClinVar: improving access to variant interpretations and supporting evidence.
Melissa J Landrum, Jennifer M Lee, Mark Benson, Garth R Brown, Chen Chao, Shanmuga Chitipiralla, Baoshan Gu, Jennifer Hart, Douglas Hoffman, Wonhee Jang,[...]. Nucleic Acids Res 2018
815
33

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Janet R Vos, Ingrid E Fakkert, Joanne A de Hullu, Anne M van Altena, Aisha S Sie, Hicham Ouchene, Riki W Willems, Iris D Nagtegaal, Marjolijn C J Jongmans, Arjen R Mensenkamp,[...]. J Natl Cancer Inst 2020
11
33

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.
Daniel C Koboldt, Qunyuan Zhang, David E Larson, Dong Shen, Michael D McLellan, Ling Lin, Christopher A Miller, Elaine R Mardis, Li Ding, Richard K Wilson. Genome Res 2012
33

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
841
33

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.
Gillian Ellison, Miika Ahdesmäki, Sally Luke, Paul M Waring, Andrew Wallace, Ronnie Wright, Benno Röthlisberger, Katja Ludin, Sabine Merkelbach-Bruse, Carina Heydt,[...]. Hum Mutat 2018
12
33

Clinical significance of large rearrangements in BRCA1 and BRCA2.
Thaddeus Judkins, Eric Rosenthal, Christopher Arnell, Lynn Anne Burbidge, Wade Geary, Toby Barrus, Jeremy Schoenberger, Jeffrey Trost, Richard J Wenstrup, Benjamin B Roa. Cancer 2012
79
33

Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
Marilyn M Li, Elizabeth Chao, Edward D Esplin, David T Miller, Katherine L Nathanson, Sharon E Plon, Maren T Scheuner, Douglas R Stewart. Genet Med 2020
25
33

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Stefania Gori, Massimo Barberis, Maria Angela Bella, Fiamma Buttitta, Ettore Capoluongo, Paola Carrera, Nicoletta Colombo, Laura Cortesi, Maurizio Genuardi, Massimo Gion,[...]. Crit Rev Oncol Hematol 2019
27
33

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
33

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
Caterina Fumagalli, Federica Tomao, Ilaria Betella, Alessandra Rappa, Mariarosaria Calvello, Bernardo Bonanni, Loris Bernard, Fedro Peccatori, Nicoletta Colombo, Giuseppe Viale,[...]. Cancers (Basel) 2019
8
33

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
673
33

CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.
Eric Talevich, A Hunter Shain, Thomas Botton, Boris C Bastian. PLoS Comput Biol 2016
480
33

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn,[...]. J Clin Oncol 2010
240
33

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
484
33

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
239
33

Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.
Melanie Care, Jeanna McCuaig, Blaise Clarke, Sylvie Grenier, Raymond H Kim, Marjan Rouzbahman, Natalie Stickle, Marcus Bernardini, Tracy L Stockley. Mol Oncol 2021
4
50

Rethinking ovarian cancer: recommendations for improving outcomes.
Sebastian Vaughan, Jermaine I Coward, Robert C Bast, Andy Berchuck, Jonathan S Berek, James D Brenton, George Coukos, Christopher C Crum, Ronny Drapkin, Dariush Etemadmoghadam,[...]. Nat Rev Cancer 2011
792
16

Targeting DNA repair: the genome as a potential biomarker.
Ksenija Nesic, Matthew Wakefield, Olga Kondrashova, Clare L Scott, Iain A McNeish. J Pathol 2018
21
16

Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.
Tamar Yablonski-Peretz, Shani Paluch-Shimon, Lior Soussan Gutman, Yulia Kaplan, Addie Dvir, Inbal Barnes-Kedar, Luna Kadouri, Valeriya Semenisty, Noa Efrat, Victoria Neiman,[...]. Breast Cancer Res Treat 2016
14
16

The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Pi-Lin Sung, Kuo-Chang Wen, Yi-Jen Chen, Ta-Chung Chao, Yi-Fang Tsai, Ling-Ming Tseng, Jian-Tai Timothy Qiu, Kuan-Chong Chao, Hua-Hsi Wu, Chi-Mu Chuang,[...]. PLoS One 2017
13
16

Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Ava Kwong, Vivian Y Shin, Jiawei Chen, Isabella W Y Cheuk, Cecilia Y S Ho, Chun H Au, Karen K L Chan, Hextan Y S Ngan, Tsun L Chan, James M Ford,[...]. J Mol Diagn 2020
3
33

Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Olivia Moran, Dina Nikitina, Robert Royer, Aletta Poll, Kelly Metcalfe, Steven A Narod, Mohammad R Akbari, Joanne Kotsopoulos. Breast Cancer Res Treat 2017
21
16

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
Laurent Castéra, Sophie Krieger, Antoine Rousselin, Angélina Legros, Jean-Jacques Baumann, Olivia Bruet, Baptiste Brault, Robin Fouillet, Nicolas Goardon, Olivier Letac,[...]. Eur J Hum Genet 2014
155
16

The mutational constraint spectrum quantified from variation in 141,456 humans.
Konrad J Karczewski, Laurent C Francioli, Grace Tiao, Beryl B Cummings, Jessica Alföldi, Qingbo Wang, Ryan L Collins, Kristen M Laricchia, Andrea Ganna, Daniel P Birnbaum,[...]. Nature 2020
16

Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients.
F Lhota, P Zemankova, P Kleiblova, J Soukupova, M Vocka, V Stranecky, M Janatova, H Hartmannova, K Hodanova, S Kmoch,[...]. Clin Genet 2016
26
16

Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Melissa K Frey, Gabriella Sandler, Rachel Sobolev, Sarah H Kim, Rachelle Chambers, Rebecca Y Bassett, Jessica Martineau, Katherine J Sapra, Leslie Boyd, John P Curtin,[...]. Gynecol Oncol 2017
14
16

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.
J Maksimenko, A Irmejs, G Trofimovičs, D Bērziņa, E Skuja, G Purkalne, E Miklaševičs, J Gardovskis. Hered Cancer Clin Pract 2018
5
20

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
201
16

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.
Jiayu Wang, Weiwei Li, Yujian Shi, Yan Huang, Tao Sun, Lili Tang, Qing Lu, Qiumo Lei, Ning Liao, Feng Jin,[...]. Cancer Med 2019
11
16

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Elodie Girard, Séverine Eon-Marchais, Robert Olaso, Anne-Laure Renault, Francesca Damiola, Marie-Gabrielle Dondon, Laure Barjhoux, Didier Goidin, Vincent Meyer, Dorothée Le Gal,[...]. Int J Cancer 2019
22
16

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
Mario Capasso, Marcella Devoto, Cuiping Hou, Shahab Asgharzadeh, Joseph T Glessner, Edward F Attiyeh, Yael P Mosse, Cecilia Kim, Sharon J Diskin, Kristina A Cole,[...]. Nat Genet 2009
214
16

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
Milagros González-Rivera, Miriam Lobo, Sara López-Tarruella, Yolanda Jerez, María Del Monte-Millán, Tatiana Massarrah, Rocío Ramos-Medina, Inmaculada Ocaña, Antoni Picornell, Sonia Santillán Garzón,[...]. Breast Cancer Res Treat 2016
21
16

Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
Katarzyna Klonowska, Magdalena Ratajska, Karol Czubak, Alina Kuzniacka, Izabela Brozek, Magdalena Koczkowska, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Magdalena Balut,[...]. Sci Rep 2015
21
16

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E Garber, Christina Herold, Leif Ellisen,[...]. Cancer 2015
252
16

Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
Piera Rizzolo, Veronica Zelli, Valentina Silvestri, Virginia Valentini, Ines Zanna, Simonetta Bianchi, Giovanna Masala, Alessandro Mauro Spinelli, Maria Grazia Tibiletti, Antonio Russo,[...]. Int J Cancer 2019
20
16

Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes.
Anna Guacci, Angela Cordella, Teresa Rocco, Giorgio Giurato, Giovanni Nassa, Francesca Rizzo, Chiara Carlomagno, Stefano Pepe, Roberta Tarallo, Alessandro Weisz. J Clin Lab Anal 2018
4
25

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Fergus J Couch, Hermela Shimelis, Chunling Hu, Steven N Hart, Eric C Polley, Jie Na, Emily Hallberg, Raymond Moore, Abigail Thomas, Jenna Lilyquist,[...]. JAMA Oncol 2017
269
16

Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
Jenna Lilyquist, Holly LaDuca, Eric Polley, Brigette Tippin Davis, Hermela Shimelis, Chunling Hu, Steven N Hart, Jill S Dolinsky, Fergus J Couch, David E Goldgar. Gynecol Oncol 2017
50
16

New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
Polina Gervas, Boris Klyuch, Evgeny Denisov, Artem Kiselev, Alexey Molokov, Lubov Pisareva, Elena Malinovskaya, Evgeny Choynzonov, Nadezda Cherdyntseva. Mol Biol Rep 2019
3
33

Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
Sylvia De Brakeleer, Jacques De Grève, Remy Loris, Nicolas Janin, Willy Lissens, Erica Sermijn, Erik Teugels. Hum Mutat 2010
59
16

Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico.
Julie Dutil, Jamie K Teer, Volha Golubeva, Sean Yoder, Wei Lue Tong, Nelly Arroyo, Rachid Karam, Miguel Echenique, Jaime L Matta, Alvaro N Monteiro. Sci Rep 2019
4
25

Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.
Yosuke Hirotsu, Hiroshi Nakagomi, Ikuko Sakamoto, Kenji Amemiya, Toshio Oyama, Hitoshi Mochizuki, Masao Omata. Mol Genet Genomic Med 2015
54
16

Next-generation sequencing in familial breast cancer patients from Lebanon.
Nadine Jalkh, Eliane Chouery, Zahraa Haidar, Christina Khater, David Atallah, Hamad Ali, Makia J Marafie, Mohamed R Al-Mulla, Fahd Al-Mulla, Andre Megarbane. BMC Med Genomics 2017
16
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.